Rosetta Genomics to Intensify Marketing Outreach for Menu of miRview Microarray Tests | GenomeWeb

Awareness, or lack thereof, is the "single greatest issue" facing Rosetta Genomics in its efforts to sell its portfolio of microRNA-based molecular diagnostics, according to CEO Kenneth Berlin.

Berlin recently told investors at the 25th Annual Roth Conference in Dana Point, Calif., that the company plans to direct around $40 million that it raised last year toward commercializing its tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.